Reparixin - CAS# 266359-83-5 10125 It was developed as a

It was developed as a replacement drug to combat bacteria that had acquired antibiotic resistance to commonly used antibiotics

Ocular hypotensive efficacy

2015 Jan 10

S-Ruxolitinib is a less active enantiomer of Ruxolitinib

Reparixin - CAS# 266359-83-5 10125 It was developed as aReparixin is an inhibitor of CXCR2 function, which attenuates inflammatory responses and promotes recovery of function after traumatic lesion to the spinal cord. In a human breast cancer cell line, both reparixin reduced the number of breast cancer stem cells compared with no treatment. I n mice with primary human breast cancer xenografts, reparixin alone or in combination with docetaxel reduced tumor growth compared with saline control. The